Sun Pharma's Q1 margins likely to be hit on elevated input costs: Analysts

margins likely to be hit on elevated input costs: Analysts

lakshmi-mittal

1 / 2

2 / 2

Also Read

Strong specialty sales and volumes keep it sunny for Sun Pharma

Sun Pharma to launch new oral lipid lowering drug under Brillo brand

Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483

Sun Pharma slips over 2% after USFDA issues observations for Halol facility

What is USFDA's Form 483?

Don't miss the most important news and views of the day. Get them on our Telegram channel